Stay updated with breaking news from Ascending Dose Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.
-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants ---- Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours ---- No Severe or Seriou...
Press release content from Business Wire. The AP news staff was not involved in its creation.
CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress
Rapid and potent C5 inhibition achieved with complete and sustained blockage of complement by a single dose of CAN106 Data to be presented at the 14th International Conference on Complement